LIPO vs. CPIX, NRBO, APLM, MEIP, KALA, SYBX, JAGX, AKTX, VBIV, and AYTU
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Cumberland Pharmaceuticals (CPIX), NeuroBo Pharmaceuticals (NRBO), Apollomics (APLM), MEI Pharma (MEIP), KALA BIO (KALA), Synlogic (SYBX), Jaguar Health (JAGX), Akari Therapeutics (AKTX), VBI Vaccines (VBIV), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical preparations" industry.
Lipella Pharmaceuticals (NASDAQ:LIPO) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
Cumberland Pharmaceuticals has a net margin of -21.67% compared to Lipella Pharmaceuticals' net margin of -992.04%. Cumberland Pharmaceuticals' return on equity of 0.21% beat Lipella Pharmaceuticals' return on equity.
Lipella Pharmaceuticals has higher earnings, but lower revenue than Cumberland Pharmaceuticals.
Lipella Pharmaceuticals has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.
Cumberland Pharmaceuticals received 186 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 44.74% of users gave Cumberland Pharmaceuticals an outperform vote.
Lipella Pharmaceuticals currently has a consensus target price of $2.00, indicating a potential upside of 214.96%. Given Lipella Pharmaceuticals' higher possible upside, equities research analysts clearly believe Lipella Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.
In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Cumberland Pharmaceuticals'average media sentiment score.
74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 39.6% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Lipella Pharmaceuticals beats Cumberland Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
